Ergomed plc

Notice of Interim Results

RNS Number : 3927J
Ergomed plc
23 August 2021
 

 PRESS RELEASE

 

 

Notice of Interim Results

 

 

Guildford, UK - 23 August 2021: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2021 on 28 September 2021.

 

Miroslav Reljanović, Executive Chairman, and Richard Barfield, Chief Financial Officer, will host a virtual presentation and conference call for analysts at 10.30am BST on the day of the results.

 

ENDS

 

Enquiries :

 

Ergomed plc                                                                               Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

 

Numis Securities Limited    Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser) 

James Black (Broker) 

 

Peel Hunt LLP                                                                             Tel: +44 (0) 20 7418 8900

James Steel / Dr. Christopher Golden

 

Consilium Strategic Communications   Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal   [email protected]

Angela Gray

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORDBGDIUBDDGBD